<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01419002</url>
  </required_header>
  <id_info>
    <org_study_id>NetPac</org_study_id>
    <nct_id>NCT01419002</nct_id>
  </id_info>
  <brief_title>Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer</brief_title>
  <acronym>Net-Pac</acronym>
  <official_title>Neoadjuvant Radiotherapy in Patients With Primary Resectable Adenocarcinoma of the Pancreatic Head Plus Adjuvant Chemotherapy: a Randomized Controlled Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHIR-Net</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CHIR-Net</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Net-Pac investigates if radiation prior to surgical resection improves survival in patients
      with pancreatic head cancer without metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is designed to show that neoadjuvant radiotherapy followed by surgery improves
      local recurrence free survival compared to surgery alone in patients with resectable
      adenocarcinoma of the pancreatic head.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of recruitment
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local recurrence free survival</measure>
    <time_frame>At 12 months postoperative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of surgical R0-resections in both groups</measure>
    <time_frame>Until 10 days postoperative</time_frame>
    <description>Determined by histopathological analysis of the surgical specimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day morbidity and mortality</measure>
    <time_frame>30 day period after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of preoperative Radiotherapy</measure>
    <time_frame>Start of the radiotherapy until 12 months postoperative.</time_frame>
    <description>Number of patients with adverse events in both groups, number of adverse events in both groups and number of grade 3 and 4 adverse events according to the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v 3.0) in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rate (RECIST-criteria) and histological response rate</measure>
    <time_frame>Until 1 year postOP</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression (local and systemic)</measure>
    <time_frame>Until 1 year postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Until 12 months postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival after 1 year</measure>
    <time_frame>Until 1 year postoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant RTx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>neoadjuvant RTx</intervention_name>
    <description>Neoadjuvant radiotherapy with external intensity modulated beam radiation followed by duodenopancreatectomy and adjuvant chemotherapy according to German S3 guidelines.</description>
    <arm_group_label>Neoadjuvant RTx</arm_group_label>
    <other_name>Intensity modulated beam radiation (IMBR).</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Surgery and adjuvant chemotherapy according to German S3-guidelines</description>
    <arm_group_label>Surgery</arm_group_label>
    <other_name>Kausch-Whipple, Pancreaticoduodenectomy, ppWhipple</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the pancreatic head

          -  Age ≥ 18 years

          -  Signed informed consent

          -  ECOG performance status of 0-2

        Exclusion Criteria:

          -  Curative resection is not feasible or presence of metastatic disease

          -  Patients not eligible for surgery (ASA ≥ 4)

          -  Participation in an other clinical trial

          -  Unable or unwilling to sign the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helmut M Friess, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Molls, Prof. MD</last_name>
    <role>Study Director</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Technische Universität München</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.chir-net-muenchen.de</url>
    <description>CHIR-Net homepage</description>
  </link>
  <link>
    <url>http://tumstrahlen.einzelportal.de/</url>
    <description>Department of Radiation Oncology, Technische Universität München</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2011</study_first_submitted>
  <study_first_submitted_qc>August 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2011</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Neoadjuvant Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

